The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC) is dedicated to research and education in cancer and related disorders and to the prompt application of new knowledge to the treatment of patients and to the prevention of neoplastic diseases. This application requests continued CCSG support for SKCCC's research programs and shared resources. The SKCCC is a multi-disciplinary, interdepartmental center of the Johns Hopkins University. There is a broad base of ongoing cancer research at Johns Hopkins. The special scientific programs of the Cancer Center are interdisciplinary in character and are focused on human disease. A wide range of activity is encompassed ranging from fundamental research into the molecular genetics of human tumorigenesis to clinical trials of new antitumor treatments. The Cancer Center has established twelve major research programs: Cancer Biology (Baylin, Velculescu), Hematologic Malignancies and BMT (Ambinder, Jones), Cancer Immunology (Pardoll), Viral Oncology (Hayward, Roden), Cancer Prevention and Control (Groopman, Platz), Chemical Therapeutics (Cole), Prostate Cancer (Carducci, Getzenberg), Breast Cancer (Stearns, Sukumar), Gastrointestinal Cancer (Jaffee, Kern) Upper Aerodigestive Cancer (Rudin, Sidransky), Brain Cancer (Grossman, Brem, Laterra), and Cancer Molecular &Functional Imaging (Bhujwalla, Pomper). Twenty-two Shared Resources support the needs of Cancer Center investigators: Animal Resources, Bioinformatics, Microarray, Cancer Functional Imaging, Cell Imaging, Common Equipment, Cytogenetics, Experimental Irradiators, Flow Cytometry, Glassware Washing, Mass Spectrometry, Specimen Accessioning Core (SAC), Tissue Microarray Core, Pharmacology Analytical Core, Human Immunology, Cell Processing and Gene Therapy, Cellular Therapy (GEL),Biostatistics, Research Pharmacy, Next Generation Sequencing, Image Response Assessment the Clinical Research Office.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006973-50S1
Application #
8710422
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1997-05-07
Project End
2017-04-30
Budget Start
2013-09-01
Budget End
2014-04-30
Support Year
50
Fiscal Year
2013
Total Cost
$43,750
Indirect Cost
$11,581
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Cuviello, Andrea; Goyal, Anshit; Zick, Aviad et al. (2018) Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF. JCO Precis Oncol 2018:
Isaacsson Velho, Pedro; Antonarakis, Emmanuel S (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11:475-486
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Dean, Lorraine T; Gehlert, Sarah; Neuhouser, Marian L et al. (2018) Social factors matter in cancer risk and survivorship. Cancer Causes Control 29:611-618

Showing the most recent 10 out of 2393 publications